591 related articles for article (PubMed ID: 25213869)
1. Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe).
Mrugala MM; Engelhard HH; Dinh Tran D; Kew Y; Cavaliere R; Villano JL; Annenelie Bota D; Rudnick J; Love Sumrall A; Zhu JJ; Butowski N
Semin Oncol; 2014 Oct; 41 Suppl 6():S4-S13. PubMed ID: 25213869
[TBL] [Abstract][Full Text] [Related]
2. Post Hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician's choice chemotherapy.
Kanner AA; Wong ET; Villano JL; Ram Z;
Semin Oncol; 2014 Oct; 41 Suppl 6():S25-34. PubMed ID: 25213871
[TBL] [Abstract][Full Text] [Related]
3. Response patterns of recurrent glioblastomas treated with tumor-treating fields.
Vymazal J; Wong ET
Semin Oncol; 2014 Oct; 41 Suppl 6():S14-24. PubMed ID: 25213870
[TBL] [Abstract][Full Text] [Related]
4. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.
Stupp R; Wong ET; Kanner AA; Steinberg D; Engelhard H; Heidecke V; Kirson ED; Taillibert S; Liebermann F; Dbalý V; Ram Z; Villano JL; Rainov N; Weinberg U; Schiff D; Kunschner L; Raizer J; Honnorat J; Sloan A; Malkin M; Landolfi JC; Payer F; Mehdorn M; Weil RJ; Pannullo SC; Westphal M; Smrcka M; Chin L; Kostron H; Hofer S; Bruce J; Cosgrove R; Paleologous N; Palti Y; Gutin PH
Eur J Cancer; 2012 Sep; 48(14):2192-202. PubMed ID: 22608262
[TBL] [Abstract][Full Text] [Related]
5. NovoTTF-100A: a new treatment modality for recurrent glioblastoma.
Fonkem E; Wong ET
Expert Rev Neurother; 2012 Aug; 12(8):895-9. PubMed ID: 22708931
[TBL] [Abstract][Full Text] [Related]
6. Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
Wong ET; Lok E; Swanson KD
Cancer Med; 2015 Mar; 4(3):383-91. PubMed ID: 25620708
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
8. The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system.
Turner SG; Gergel T; Wu H; Lacroix M; Toms SA
World J Surg Oncol; 2014 May; 12():162. PubMed ID: 24884522
[TBL] [Abstract][Full Text] [Related]
9. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
[TBL] [Abstract][Full Text] [Related]
10. Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma.
Lacouture ME; Davis ME; Elzinga G; Butowski N; Tran D; Villano JL; DiMeglio L; Davies AM; Wong ET
Semin Oncol; 2014 Jun; 41 Suppl 4():S1-14. PubMed ID: 24794308
[TBL] [Abstract][Full Text] [Related]
11. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Kesari S; Ram Z;
CNS Oncol; 2017 Jul; 6(3):185-193. PubMed ID: 28399638
[TBL] [Abstract][Full Text] [Related]
12. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
[TBL] [Abstract][Full Text] [Related]
13. The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.
Burri SH; Gondi V; Brown PD; Mehta MP
Am J Clin Oncol; 2018 Feb; 41(2):191-196. PubMed ID: 28832384
[TBL] [Abstract][Full Text] [Related]
14. Delayed response and survival from NovoTTF-100A in recurrent GBM.
Villano JL; Williams LE; Watson KS; Ignatius N; Wilson MT; Valyi-Nagy T; Michals EA; Engelhard HH
Med Oncol; 2013 Mar; 30(1):338. PubMed ID: 23307238
[TBL] [Abstract][Full Text] [Related]
15. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.
Chan TA; Weingart JD; Parisi M; Hughes MA; Olivi A; Borzillary S; Alahakone D; Detorie NA; Wharam MD; Kleinberg L
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1133-9. PubMed ID: 15990019
[TBL] [Abstract][Full Text] [Related]
16. Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma.
Wong ET; Lok E; Swanson KD; Gautam S; Engelhard HH; Lieberman F; Taillibert S; Ram Z; Villano JL
Cancer Med; 2014 Jun; 3(3):592-602. PubMed ID: 24574359
[TBL] [Abstract][Full Text] [Related]
17. Outcome of treatment of recurrent glioblastoma multiforme in elderly and/or frail patients.
Socha J; Kepka L; Ghosh S; Roa W; Kumar N; Sinaika V; Matiello J; Lomidze D; de Castro DG; Hentati D; Fidarova E
J Neurooncol; 2016 Feb; 126(3):493-8. PubMed ID: 26542030
[TBL] [Abstract][Full Text] [Related]
18. Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution.
Azoulay M; Santos F; Shenouda G; Petrecca K; Oweida A; Guiot MC; Owen S; Panet-Raymond V; Souhami L; Abdulkarim BS
J Neurooncol; 2017 May; 132(3):419-426. PubMed ID: 28374095
[TBL] [Abstract][Full Text] [Related]
19. Can MRI-derived factors predict the survival in glioblastoma patients treated with postoperative chemoradiation therapy?
Nakamura H; Murakami R; Hirai T; Kitajima M; Yamashita Y
Acta Radiol; 2013 Mar; 54(2):214-20. PubMed ID: 23138021
[TBL] [Abstract][Full Text] [Related]
20. New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials.
Gorlia T; Stupp R; Brandes AA; Rampling RR; Fumoleau P; Dittrich C; Campone MM; Twelves CC; Raymond E; Hegi ME; Lacombe D; van den Bent MJ
Eur J Cancer; 2012 May; 48(8):1176-84. PubMed ID: 22464345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
